A Safety Lead-In/Randomized Phase 2 Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs BMX 001 (Primary)
- Indications Brain metastases
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioMimetix
- 04 Oct 2018 Status changed from not yet recruiting to recruiting.
- 15 Aug 2018 Planned primary completion date changed from 31 Jul 2022 to 31 Aug 2022.
- 15 Aug 2018 Planned initiation date changed from 1 Aug 2018 to 13 Sep 2018.